BioMed Research International / 2015 / Article / Tab 2

Research Article

miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib

Table 2

Validation of miR-155 and miR-484 on the independent cohort () and their correlation with TTP (months).

Number of patients ()Median TTP (months)Log-rank HR95% CI

miR-155
 Low, <0.23814212.80.00922.4121.243–4.680
 High, ≥0.2381215.8
miR-484
 Low, <1.4408528.90.02962.6231.100–6.254
 High, ≥1.4408115.8